Ghanim Khatib

Prof. Ghanim Khatib

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
MVMehmet Ali Vardar
Mehmet Ali Vardar
UGUmran Kucukgoz Gulec
Umran Kucukgoz Gulec
AGAhmet Baris Guzel
Ahmet Baris Guzel
DGDerya Gumurdulu
Derya Gumurdulu
GKGhanim Khatib
Ghanim Khatib
GSGulsah Seydaoglu
Gulsah Seydaoglu
Vardar MA, et al. J Gynecol Oncol. 2018 Aug;30:e24. https://doi.org/10.3802/jgo.2019.30.e24

20 April 2016 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
PDF file
CÇCihan Çetin
Cihan Çetin
CSCenk Soysal
Cenk Soysal
GKGhanim Khatib
Ghanim Khatib
IUIbrahim Ferhat Urunsak
Ibrahim Ferhat Urunsak
TCTuran Cetin
Turan Cetin

22 August 2013 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
UGUmran Kucukgoz Gulec
Umran Kucukgoz Gulec
DGDerya Gumurdulu
Derya Gumurdulu
AGAhmet Baris Guzel
Ahmet Baris Guzel
SPSemra Paydas
Semra Paydas
GSGulsah Seydaoglu
Gulsah Seydaoglu
AAAytekin Altintas
Aytekin Altintas

4 December 2020 in Journal of the Turkish-German Gynecological Association
Verified
Journal Article
Closed access
DADuygu Altın
Duygu Altın
IYİbRahim Yalçın
İbRahim Yalçın
GKGhanim Khatib
Ghanim Khatib
MKMine Dağgez Keleşoğlu
Mine Dağgez Keleşoğlu
SASedat Akgol
Sedat Akgol
FDFuat Demirkíran
Fuat Demirkíran
This study aimed to investigate how gynecologic oncologists modified their patient management during Coronavirus disease-2019 (COVID-19) in Turkey. An online survey was sent to gynecologic oncology specialists and fellows in Turkey. It included management questions about strategies for newly diagnosed or recurrent endometrial, cervical, ovarian and vulvar cancer during the pandemic. Participants were asked if treatment of these cancers can be delayed or not and, if yes, the duration of delay. 32.9% of surgeons prescribed oral or intrauterine progesterone for early stage, low-grade endometrial cancer. Conversely, 65.7% and 45.7% of the most surgeons did not change their management for early stage high-grade and advanced stage endometrial cancers respectively, as they perform surgery. 58% and 67.1% of the surgeons continued to prefer standard surgical treatment for microinvasive and early stage cervical cancers, respectively. Radiotherapy was preferred administered with hypofractionated doses for locally advanced cervical cancer (57.1%). While 67.1% of surgeons operated early stage ovarian cancer patients, 50% administered neoadjuvant chemotherapy (NACT) to all advanced stage ovarian cancers and 50% administered more cycles of NACT in preference to interval debulking surgery. 93.7% of the surgeons responded that treatment should not be delayed beyond eight weeks. Most Turkish gynecologic oncologists modified their management of gynecologic cancers due to the COVID-19 pandemic. While chemotherapy was preferred for ovarian cancer, postponement of the surgery, with or without non-surgical options, was considered for early stage, low-grade endometrial cancer. Treatment of gynecologic cancers should be decided on a case by case basis, taking into account local COVID-19 infection rates and availability of health facilities. Prognosis is also an important consideration if delay is contemplated. Standard treatment and normal time-frames should be used if possible. If not, a postponement for a maximum of eight weeks or referral to another center were acceptable alternatives.

27 February 2013 in Journal of Obstetrics and Gynaecology
Verified
Journal Article
Closed access
GKGhanim Khatib
Ghanim Khatib
AGA. B. Guzel
A. B. Guzel
UKU. Kucukgoz-Gulec
U. Kucukgoz-Gulec
MVM. A. Vardar
M. A. Vardar
AMA. Musaev
A. Musaev
Rauf MelekogluRauf Melekoglu
Rauf Melekoglu
Teratoma of the fallopian tube (cystic or solid) is a rarely encountered tumour and, to date, only 73 cases have been reported in the literature. A comprehensive review has not been done since 1972, when Mazzarella and colleagues reviewed 44 cases of tubal teratomas. This situation has prompted us to survey the literature to update the data on tubal teratoma cases. The majority of the tumours were benign. The tumour was cystic in nature in 50 cases. Patients’ ages ranged between 17 and 67 years. None of them was diagnosed preoperatively. Half of the tumours were ≤ 5 cm, whereas the other half were > 5 cm in diameter. About two-thirds of the patients were associated with two or fewer gravidity. To the best of our knowledge, the present case included in our paper is the first tubal cystic teratoma reported from Turkey.

2 October 2020 in Journal of Turkish Society of Obstetric and Gynecology
Verified
Journal Article
Open access
AGAhmet Barış Güzel
Ahmet Barış Güzel
GKGhanim Khatib
Ghanim Khatib
UGUmran Kucukgoz Gulec
Umran Kucukgoz Gulec
DGDerya Gumurdulu
Derya Gumurdulu
MVMehmet Ali Vardar
Mehmet Ali Vardar
Morbid obesity is identified as patients with a body mass index more than 40 kg/m2. Obesity is known as a risk factor for endometrial cancer due to the increase of the deposited estrogen. This study was conducted to evaluate the effect of morbid obesity on the survival of endometrial cancer. The archival records and pathologic reports of patients with endometrial cancer who underwent surgery and were followed up in Çukurova University Gynecologic Oncology Center between January 1996 and December 2018 were reviewed, retrospectively. Data regarding body mass index and survival was reported in 520 patients. These patients were stratified into two groups according to their body mass index, <40 and ≥40 kg/m2. The groups’ clinic, pathologic features, and survival rates were compared. There were 146 patients in the morbidly obese group and 374 patients in the obese group. The mean age of the groups was 58.5 and 56.2 years, respectively. The mean follow-up time was 51.6 months. Comorbidities were significantly higher in the morbidly obese group. The five-year disease-free and overall survival rates were 78.3% and 85.3% in the morbidly obese group, and 81.6% and 90.1% in the obese group, respectively. Although the groups’ clinical and pathologic features were homogeneously distributed, disease-free and overall survival rates were significantly different (p=0.053 and p=0.054, respectively). Morbidly obese patients with endometrial cancer were associated with 2.7-fold increased risk of death and 1.7-fold increased risk of recurrence compared with those who had body mass index <40 kg/m2. It is important to deal with the frequent comorbidities in this special group, which could be simply altered by lifestyle changes. Morbidly obese patients with endometrial cancer should be encouraged in lifestyle changes and consulted by dieticians and endocrinologists.